Ami Patel, MD
Internal Medicine · Wilmington, NCNPI 1407895907
Payments from drug & device makers
Across 186 payments — averaging $16.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$666
- AstraZeneca$482
- Lilly USA, LLC$319
- AbbVie$280
- Intra-sana Laboratories$167
- Pfizer$157
- plus $912 from 24 others
What the payments were for
- Food & beverage$2,95199%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 44 | $666 |
| AstraZeneca | 22 | $482 |
| Lilly USA, LLC | 19 | $319 |
| AbbVie | 15 | $280 |
| Intra-sana Laboratories | 24 | $167 |
| Pfizer | 9 | $157 |
| Boehringer Ingelheim | 4 | $90 |
| Phathom Pharmaceuticals, Inc. | 7 | $88 |
| Astellas Pharma US Inc | 4 | $77 |
| Bausch Health US, LLC | 4 | $69 |
| Ironwood Pharmaceuticals, Inc | 4 | $63 |
| Idorsia Pharmaceuticals US Inc | 4 | $61 |
| Axsome Therapeutics, Inc. | 3 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $42 |
| Exact Sciences | 2 | $37 |
| Currax Pharmaceuticals LLC | 2 | $35 |
| Acella Pharmaceuticals, LLC | 2 | $34 |
| Amgen(2 entities) | 2 | $33 |
| Actelion Pharmaceuticals US, Inc. | 1 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Johnson & Johnson | 1 | $22 |
| Abbott | 1 | $22 |
| Merck | 1 | $16 |
| Scynexis, Inc. | 1 | $15 |
| Exeltis, USA Inc. | 1 | $14 |
| Adlon Therapeutics L.p. | 1 | $14 |
| Assertio Therapeutics, Inc. | 1 | $13 |
| Almatica Pharma LLC | 1 | $13 |
| IBSA Pharma Inc. | 1 | $12 |
How this compares
$2,984 in reported general payments places this provider in the 80th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 69 | $77,997 |
| MounjaroTirzepatide | 67 | $71,576 |
| JardianceEmpagliflozin | 21 | $14,981 |
| EliquisApixaban | 18 | $9,562 |
| PremarinEstrogens, Conjugated | 20 | $6,779 |
| SynthroidLevothyroxine Sodium | 28 | $3,245 |
| Colesevelam Hcl | 18 | $2,179 |
| Metoprolol Succinate | 173 | $2,099 |
| Levothyroxine Sodium | 206 | $2,003 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $1,954 |
| Olmesartan Medoxomil | 80 | $1,772 |
| Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid | 12 | $1,698 |
| Estradiol | 24 | $1,649 |
| Losartan Potassium | 155 | $1,463 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 54 | $1,439 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $666 | $77,99769 claims |
| Lilly USA, LLCMounjaro | $319 | $71,57667 claims |
| PfizerEliquis, Premarin, Paxlovid | $157 | $17,77049 claims |
| Boehringer IngelheimJardiance | $90 | $14,98121 claims |
| AbbVieSynthroid | $280 | $3,24528 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Wilmington
- Brian WebsterWilmington$3.7M
- Hector SanchezWilmington$770K
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- John RubinoRaleigh$13M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Sylvia ShoffnerCary$7.1M
- Wayne HarperRaleigh$6.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.